These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23752789)

  • 21. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
    Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
    Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
    Quan A
    Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study.
    Hudson M; Rahme E; Behlouli H; Sheppard R; Pilote L
    Eur J Heart Fail; 2007; 9(6-7):602-9. PubMed ID: 17383932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β-blockers after coronary artery bypass graft surgery.
    Kalavrouziotis D; Buth KJ; Cox JL; Baskett RJ
    Am Heart J; 2011 Nov; 162(5):836-43. PubMed ID: 22093199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
    Kalaitzidis R; Bakris G
    Postgrad Med; 2009 Mar; 121(2):77-88. PubMed ID: 19332965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial.
    Kiski D; Stepper W; Brand E; Breithardt G; Reinecke H
    Nephrol Dial Transplant; 2010 Mar; 25(3):759-64. PubMed ID: 19903660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P
    Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
    Barrios V; Coca A; Escobar C; Enrique R; Rincón LM
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.
    Kheterpal S; Khodaparast O; Shanks A; O'Reilly M; Tremper KK
    J Cardiothorac Vasc Anesth; 2008 Apr; 22(2):180-6. PubMed ID: 18375317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.
    Weber MA
    Rev Cardiovasc Med; 2002; 3(4):183-91. PubMed ID: 12556752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteinuria, a modifiable risk factor: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).
    Dykeman-Sharpe J
    CANNT J; 2003; 13(4):34-6; quiz 37-8. PubMed ID: 14753101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reviewing the future of renin-angiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation.
    Ducharme A; Schiffrin EL
    Can J Cardiol; 2010 Dec; 26 Suppl E():21E-23E. PubMed ID: 21620287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.